F.D.A. Approves GHB, a ‘Date Rape’ Drug, for Rare Sleeping Disorder

Jazz Pharmaceuticals brought in more than $1.7 billion last year selling GHB to narcolepsy patients. With the new approval, sales could soar.

View original article
Contributor: Virginia Hughes